Hybrid enzyme-polymeric capsules/mesoporous silica nanodevice for in situ cytotoxic agent generation

Advanced Functional Materials

Volumn 24, Issue 29, 2014, Pages 4625-4633

  Baeza, Alejandro ^a   Guisasola, Eduardo ^a   Torres Pardo, Almudena ^b   González Calbet, José M ^b   Melen, Gustavo J ^c   Ramirez, Manuel ^c   Vallet Regí, Maria ^a  

^a BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

drug delivery; enzyme nanocapsules; in situ cytotoxic generation; mesoporous silica nanoparticles; prodrug release

Indexed keywords

BIOLOGY; DRUG DELIVERY; ENZYME ACTIVITY; ENZYME INHIBITION; NANOSTRUCTURED MATERIALS; SILICA;

BIOLOGICAL MEDIA; CONFORMATIONAL CHANGE; CYTOTOXIC; CYTOTOXIC AGENTS; CYTOTOXIC SPECIES; LIVING ORGANISMS; MESOPOROUS SILICA NANOPARTICLES; PRODRUGS;

POLYMERS;

EID: 84902487824     PISSN: 1616301X     EISSN: 16163028     Source Type: Journal    
DOI: 10.1002/adfm.201400729     Document Type: Article

References (41)

1. a) I. Brigger, C. Dubernet, P. Couvreur, Adv. Drug Delivery Rev. 2012, 64, 24-36
2. b) A. Schroeder, D. A. Heller, M. M. Winslow, J. E. Dahlman, G. W. Pratt, R. Langer, T. Jacks, D. G. Anderson, Nat. Rev. Cancer 2012, 12, 39-50
3. c) A. H. Faraji, P. Wipf, Bioorg. Med. Chem. 2009, 17, 2950-2962.
4. H. Maeda, H. Nakamura, J. Fang, Adv. Drug Delivery Rev. 2013, 65, 71-79.
5. R. K. Jain, T. Stylianopoulos, Nat. Rev: Clin. Oncol. 2010, 7, 653-664.
6. a) J. H. Adair, M. P. Parette, E. I. Altinoglu, M. Kester, ACS Nano 2010, 4, 4967-4970
7. b) W. B. Liechty, N. A. Peppas, Eur. J. Pharm. Biopharm. 2012, 80, 241-246
8. c) F. M. Kievit, M. Zhang, Acc. Chem. Res. 2011, 44, 853-862
9. d) M. Colilla, B. González, M. Vallet-Regí, Biomater. Sci. 2013, 1, 114-134.
10. a) F. Tang, L. Li, D. Chen, Adv. Mater. 2012, 24, 1504-1534
11. b) M. Vallet-Regí, M. Manzano, M. Colilla, in Biomedical applications of mesoporous ceramics, CRC Press, Boca Ratõn, FL 2013
12. c) J. Simmchem, A. Baeza, D. Ruiz-Molina, M. J. Esplandiu-Egido, M. Vallet-Regí, Small 2012, 8, 2053-2059.
13. a) M. Vallet-Regí, E. Ruiz-Hernández, Adv. Mater. 2011, 23, 5177-5218
14. b) M. Vallet-Regí, E. Ruiz-Hernández, B. González, A. Baeza, J. Biomat. Tissue Eng. 2011, 1, 6-29
15. c) Z. Li, J. C. Barnes, A. Bosoy, J. F. Stoddart, J. I. Zink, Chem. Soc. Rev. 2012, 41, 2590-2605
16. d) V. Mamaeva, C. Sahlgren, M. Lindén, Adv. Drug Delivery Rev. 2013, 65, 689-702.
17. J. Lu, M. Liong, Z. Li, J. I. Zink, F. Tamanoi, Small 2010, 6, 1794-1805.
18. Y. Zhao, X. Sun, G. Zang, B. G. Trewyn, I. I. Slowing, V. S-Y. Lin, ACS Nano 2011, 5, 1366-1375.
19. a) A. Baeza, E. Guisasola, E. Ruiz-Hernández, M. Vallet-Regí, Chem. Mater. 2012, 24, 517-524
20. b) E. Ruiz-Hernández, A. Baeza, M. Vallet-Regí, ACS Nano 2011, 5, 1259-1266.
21. V. J. Venditto, F. C. Szoka Jr, Adv. Drug Delivery Rev. 2013, 65, 80-88.
22. a) A. Popat, B. P. Ross, J. Liu, S. Jambhrunkar, F. Kleitz, S. Z. Qiao, Angew. Chem. Int. Ed. 2012, 51, 12486-12489
23. b) D. Niculescu-Duvaz, G. Negoita-Giras, I. Niculescu-Duvaz, D. Hedley, C. J. Springer, in Prodrugs and Targeted Delivery: Towards Better ADME Properties, (Ed:, Jarkko Rautio,) Wiley-VCH, Weinheim, 2011, pp 271-344.
24. J. Rautio, H. Kumpulainen, T. Heimbach, R. Oliyai, D. Oh, T. Järvinen, J. Savolainen, Nat. Rev. Drug Discovery 2008, 7, 255-270.
25. M. Rooseboom, J. N. N. Commandeur, N. P. E. Vermeulen, Pharmacol. Rev. 2004, 56, 53-102.
26. a) D. S. Kim, S. E. Jeon, K. C. Park, Cell. Signal. 2004, 16, 81-88
27. b) M. P. de Melo, T. M. de Lima, T. C. Pithon-Curi, R. Curi, Toxicol. Lett. 2004, 148, 103-111.
28. S. M. P. Pugine, P. Brito, T. C. Alba-Loureiro, E. J. X. Costa, R. Curi, M. P. de Melo, Cell Biochem. Funct. 2007, 25, 723-730.
29. L. R. B. Mourão, R. S. S. Santana, L. M. Paulo, S. M. P. Pugine, L. M. Chaible, H. Fukumasu, M. L. Z. Dagli, M. P. de Melo, Cell Biochem. Funct. 2009, 27, 16-22.
30. C. Mateo, J. M. Palomo, G. Fernandez-Lorente, J. M. Guisan, R. Fernandez-Lafuente, Enz. Microbial Technol. 2007, 40, 1451-1463.
31. C. O. Fagain, Biochim. Biophys. Acta 1995, 1252, 1-14.
32. F. Hoffmann, M. Cornelius, J. Morell, M. Fröba, Angew. Chem. Int. Ed. 2006, 45, 3216-3251.
33. F. Lu, S-H. Wu, Y. Hung, C-Y. Mou, Small 2009, 5, 1408-1413.
34. a) I. I. Slowing, B. G. Trewyn, V. S-Y. Lin, J. Am. Chem. Soc. 2007, 129, 8845-8849
35. b) A. Vila, A. Sánchez, M. Tobío, P. Calvo, M. J. Alonso, J. Controlled Release 2002, 78, 15-24.
36. a) O. Greco, S. Rossiter, C. Kanthou, L. K. Folkes, P. Wardman, G. M. Tozer, G. U. Dachs, Mol. Cancer Ther. 2001, 1, 151-160
37. b) I. Niculescu-Duvaz, R. Spooner, R. Marais, C. J. Springer, Bioconjugate Chem. 1998, 9, 4-22.
38. a) Y. Liu, J. Du, M. Yan, M. Y. Lau, J. Hu, H. Han, O. O. Yang, S. Liang, W. Wei, H. Wang, J. Li, X. Zhu, L. Shi, W. Chen, C. Ji, Y. Lu, Nat. Nanotechnol. 2013, 8, 187-192
39. b) M. Yan, J. Du, Z. Gu, M. Liang, Y. Hu, W. Zhang, S. Priceman, L. Wu, Z. H. Zhou, Z. Liu, T. Segura, Y. Tang, Y. Lu, Nat. Nanotechnol. 2010, 5, 48-53.
40. P. Trinder, D. Webster, Ann. Clin. Biochem. 1984, 21, 430-433.
41. L. K. Folkes, P. Wardman, Biochem. Pharmacol. 2001, 61, 129-136.